Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:38 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1262

Shown on this page

Current sort

Live official records

Conditions: Breast Cancer
Interventions: Placebo, GLSI-100; Biological
Lead sponsor: Greenwich LifeSciences, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 51
States / cities: Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more

Conditions: Neutropenia
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 19 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Interventions: Endogenex Treatment, Sham Procedure; Device
Lead sponsor: Endogenex, Inc.; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Gardena, California • Los Angeles, California + 24 more

Conditions: Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Interventions: Nivolumab, Ipilimumab, Surgical Procedure, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Biological · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 132
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 74 more

Conditions: Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma, Central Nervous System Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)
Interventions: Long-term Follow-Up; Other
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 11
States / cities: Gilbert, Arizona • Stanford, California • New Haven, Connecticut + 8 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Interventions: Pembrolizumab, Patient Observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment; Biological · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 828
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more

Conditions: Type 2 Diabetes, High Blood Pressure
Interventions: Polypill, Combined prescription of the individual medications; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Interventions: Acoramidis, Placebo oral tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 31 more

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, RFC1 Gene Mutation, Spinocerebellar Ataxia Type 27b, Healthy Participants
Interventions: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, Assessments and Questionnaires, Cerebrospinal Fluid Collection; Genetic · Other
Lead sponsor: Lauren Moore; Other
Eligibility: 6 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 12 more

About this UT Southwestern Medical Center institution page

What this page lists: ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UT Southwestern Medical Center

Filter and sort this campus

Live official records

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Polypill for Prevention of Cardiomyopathy

PET/MR for Characterization of Renal Masses (RMs)

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

About this UT Southwestern Medical Center institution page